General MedicationsOPHTHALMICGeneric
XELPROS
LATANOPROST
Standard Dose
0.005%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview XELPROS is listed in Drugs@FDA under application 206185 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient LATANOPROST Form and strength EMULSION;OPHTHALMIC - 0.005% Sponsor SUN PHARM Submission history Latest submission status date: 2024-10-09 00:00:00.
Structured Monograph
Clinical summary
Approval overview XELPROS is listed in Drugs@FDA under application 206185 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LATANOPROST Form and strength EMULSION;OPHTHALMIC - 0.005% Sponsor SUN PHARM Submission history Latest submission status date: 2024-10-09 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.